In July 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:
- Imbruvica▼(ibrutinib) and risk of hepatitis B reactivation:
- Zinbryta▼ (daclizumab):
- Aflibercept (Zaltrap▼) concentrate for solution for infusion 200 mg/8 mL: some batches contain previous Patient Information Leaflet;
- Valproate medicines: only for use when no other treatment is effective or tolerated in girls, women of childbearing potential, and women who are pregnant or planning pregnancy; important actions required —
- Shortage of Trisenox (arsenic trioxide, 1 mg/ml concentrate for solution for infusion): off-label or unlicensed use of medicines
— prescribers should refer responsibilities for
Article citation: Drug Safety Update volume 11 issue 1, August 2017: 4.